Response to the Letter to the Editor by Susan Thorpe et al.: How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response

Cytokine

Volumn 64, Issue 1, 2013, Pages 473-475

  Wolf, Babette ^a   Morgan, Hannah ^a   Brennan, Frank ^a,b   Krieg, Jennifer ^a,c   Gani, Zaahira ^a   Jones, Stewart ^a   Kiessling, Andrea ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UCB PHARMA   (Belgium)

^c MOLECULAR PARTNERS AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD4 ANTIGEN; CETUXIMAB; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; ORTHOCLONE; PANITUMUMAB; RITUXIMAB; TGN 1412; TGN 1412L; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; CD4+ T LYMPHOCYTE; CONCENTRATION (PARAMETERS); CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; CYTOKINE RESPONSE; HUMAN; IMMUNOASSAY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LETTER; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOKINES; HUMANS; IMMUNE SYSTEM DISEASES;

EID: 84883561276     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.07.014     Document Type: Letter

References (10)

1. Wolf B., Morgan H., Krieg J., Gani Z., Milicov A., Warncke M., et al. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. Cytokine 2012, 60:828-837.
2. Bailey L, Moreno L, Manigold T, Krasniqi S, Kropshofer H, Hinton H, et al. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. J Pharmacol Toxicol Methods 2012 [Epub ahead of print].
3. Findlay L., Eastwood D., Ball C., Robinson C.J., Bird C., Wadhwa M., et al. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Methods 2011, 371:134-142.
4. Walker M.R., Makropoulos D.A., Achuthanandam R., Van Arsdell S., Bugelski P.J. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis. Int Immunopharmacol 2011, 11:1697-1705.
5. Eastwood D., Bird C., Dilger P., Hockley J., Findlay L., Poole S., et al. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Brit J Clin Pharmacol 2013, 76:299-315.
6. Stebbings R., Eastwood D., Poole S., Thorpe R. After TGN1412: recent developments in cytokine release assays. J Immunotoxicol 2013, 10:75-82.
7. Dhir V., Fort M., Mahmood A., Higbee R., Warren W., Narayanan P., et al. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J Immunotoxicol 2012, 9:34-42.
8. Römer P.S., Berr S., Avota E., Na S.Y., Battaglia M., ten Berge I., et al. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011, 118:6772-6782.
9. Wing M. Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol 2008, 5:11-15.
10. Vidal JM, Kawabata TT, Thorpe R, Silva-Lima B, Cederbrant K, Poole S, et al. In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency workshop. Cytokine 2010;51:213-5.